
Andrew Blauvelt, MD, MBA, reviews clinical implications from the phase 3 LIBERTY AD CHRONOS study examining the efficacy of dupilumab plus topical corticosteroids in adult patients with moderate to severe atopic dermatitis.

Andrew Blauvelt, MD, MBA, reviews clinical implications from the phase 3 LIBERTY AD CHRONOS study examining the efficacy of dupilumab plus topical corticosteroids in adult patients with moderate to severe atopic dermatitis.

An expert dermatologist provides key takeaways and the real-world significance of dupilumab use for the treatment of atopic dermatitis.

Terri Phillips, MD, FAAP, expands on her letter to the editor in the April issue of Dermatology Times® diving into how her experience has shaped the her view of the aesthetics industry, the challenges both physicians and patients face, and more.

In this week’s Pointers with Dr Portela, the 208SkinDoc attended the 2022 American Academy of Dermatology (AAD) Annual Meeting and talked to several dermatologists about skin care and common misconceptions about this topic.

What are the best post- and pre-lightening products and strategies for optimal results on all skin types? Renata Block, president of the Society of Dermatology Physician Assistants, walked through her pearls in this interview at the American Academy of Dermatology 2022 Annual Meeting.

Renata Block, MMS, PA-C, president of the Society of Dermatology Physician Assistants (PAs) talked with Dermatology Times® at the American Academy of Dermatology 2022 Annual Meeting about the broadening opportunities for these advanced health care providers to help fill the demand gap for treatment of skin and hair disorders as well as aesthetic services.

In this drug pipeline video, Pearl Grimes, MD, FAAD, and Seemal R. Desai, MD, FAAD discuss what's currently happening in the vitiligo pipeline including why current treatments are lacking, what's coming soon, and what it may cost.

VisualDX uses diverse imagery to help increase knowledge of disease manifestations in a range of skin types.

In this fourth part of a 4 part video series, Lisa Zaba, MD, PhD, FAAD, talks about what to look forward to in treatment and clinical trials of merkel cell carcinoma (MCC).

In this third part of a 4 part video series, Lisa Zaba, MD, PhD, FAAD, highlights the in practice experiences in using circulating tumor DNA for merkel cell carcinoma (MCC).

Dr Andrew Blauvelt reviews key highlights and clinical implications from the LIBERTY AD OLE study assessing the effect of long-term dupilumab treatment on efficacy improvements in adults with moderate to severe atopic dermatitis.

Andrew Blauvelt, MD, MBA, reviews recent advances in the therapeutic landscape for moderate to severe atopic dermatitis.

Christopher Bunick, MD, PhD, offered pointers on how to address the physical and mental aspects of this complex disease in this exclusive interview in conjunction with the American Academy of Dermatology 2022 Annual Meeting.

In this first part of a 4 part video series, Lisa Zaba, MD, PhD, FAAD, explains the science behind her presentation on "The Utility of Circulating Tumor DNA for Detecting Clinically Evident and Occult Merkel Cell Carcinoma." This was presented at the 2022 American Academy of Dermatology Annual Meeting.

In this week’s Pointers with Dr Portela, the 208SkinDoc answers the question, “Should I be taking a collagen supplement?” He breaks down the evidence as the answer is not as simple as it may seem.

In this video interview, Peter A. Lio, MD, FAAD , discusses his presentation about pain-free dermatology at the 2022 American Academy of Dermatology annual meeting. We talk strategies, benefits, and more.

In this video interview, Adam J. Friedman, MD, FAAD, gives the highlights from his presentation at the 2022 American Academy of Dermatology annual meeting about dietary triggers in acne, providing evidence, and discussing how the idea came to be.

In this video interview, we sit down with both Jennifer Lin Hsiao, MD, FAAD, and Scott Worswick, MD, FAAD, to talk in detail about their presentation, "Hidradenitis Suppurativa and Pityriasis Rubra Pilaris: Updates on Treatments for Two Conditions that are Difficult to Manage."

In this video interview, Christopher Bunick, MD, PhD dives into the topic of congenital ichthyosis describing his talk on the skin condition at the American Academy of Dermatology 2022 Annual Meeting.

Christopher Bunick, MD, PhD, talked about his presentation at the 2022 American Academy of Dermatology Annual Meeting on acne, which included a review of updated information on acne and practice pearls.

In this video interview, we sit down with Natasha Atanaskova Mesinkovska, MD, PhD, FAAD, to discuss her 2022 AAD annual meeting presentation on alopecia areata. We dive into pipeline possibilities, what current treatments are missing, and more.

In this week’s Pointers with Dr Portela, the 208SkinDoc discusses how treatments are often too expensive for patients, which causes them to be labeled as “non-compliant.” He discusses ways to improve adherence for both patients and doctors

An expert dermatologist evaluates the role of dupilumab in decreasing the clinical burden of severe atopic dermatitis on patients and their caregivers and shares insight on the future outlook of dupilumab in disease management.

Benjamin Lockshin, MD, FAAD, reviews key findings from a phase 2 trial evaluating the safety and efficacy of single-dose dupilumab in children with severe atopic dermatitis.

Benjamin Lockshin, MD, FAAD, comments on the significance of recent expansions of therapeutics options for patients with atopic dermatitis and unmet needs in the field.



Panelists share parting advice and key takeaways on the optimal management of atopic dermatitis within the treatment landscape.

Experts share insight on the challenges inherent in treating patients with atopic dermatitis despite recent advances in therapy.

In this video the OJM group talks about volatile markets and how to navigate investing in uncertain times.